Hippokratia 2014, 18(1):95

Diamantidis MD1, Kostopoulos Ι2, Kaiafa GD1
1Haematology Department, First Propedeutic Department of Internal Medicine, 2Department of Pathology AHEPA General Hospital, Aristotle University, Thessaloniki, Greece


Read PDF

Key words: Immunoproliferative small intestinal disease, alpha heavy chain disease, lymphoma

Corresponding author: Michael D. Diamantidis, MSc, PhD, Haematologist, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dear Editor,

A 30-year-old male presented having diarrhoea and abdominal pain since 14 months. Previous investigations identified no disease. Computed Tomography showed mesenteric and retroperitoneal lymphadenopathy with diffuse inflammation and intestinal dilatation. Duodenal and ileac biopsies revealed immunoproliferative small intestinal disease (IPSID), a rare lymphoma also called alpha heavy chain disease1.

The bowel lamina propria was infiltrated mainly with plasma cells expressing monoclonal cytoplasmic truncated alpha heavy chain without light chain restriction. Histopathology is shown in Figure 1. Hypogammaglobulinemia, due to defective heavy chain assembly, mild anemia and hypoalbuminemia were present. Bone marrow aspiration was normal.

Figure 1. Small intestinal biopsy. Flattened mucosa dif- fusely infiltrated by plasma cells (A), positive to CD138 (B) and MUM1/IRF4 (C) antigens with cytoplasmic ex- pressionofIgAheavychain(D)(A:Hematoxylin & Eosin, x100, B-D: IHC, x100).

The patient underwent six cycles of bi-weekly chemotherapy with cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), vincristine (1.4 mg/m2) and prednisolone (50 mg/m2/day) (CHOP). However, his symptoms deteriorated with massive mesenteric lymphadenopathy. He denied further treatment and died hospitalized in his country, after 4 months.

IPSID is variant of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT), with defective alpha heavy chains secreted, observed in Mediterranean young adults with peak incidence in second and third decades. The malignant cells have lymphoplasmacytic phenotype2. Salem and Estephan proposed a novel staging system, combining the complementary former Galian and Salem systems and integrating cytological grade, submucosal involvement and anatomical stage of the lymphoma overall3.

Middle East studies indicate decline in its incidence over the last 3 decades. This is explained by improved socioeconomic and hygienic conditions (vaccinations programs, decrease in malnutrition and intestinal infections), but also because of increased antibiotics use and decreased incidence of Campylobacter jejuni,which has been linked with IPSID, through chronic antigenic stimulation.Antimicrobial therapy with tetracycline, ampicillin or metronidazole is effective in early-stage IPSID, which may completely remit, showing the importance of early diagnosis. However, many patients experience transformation to diffuse large B-cell lymphoma (DLBCL), or distant metastases and fatal outcomes are frequent2. We conclude that IPSID transformed to DLBCL in our patient, because of his clinical course. Treatment with anthracycline regimens results in remission and longer survival2.

Conflict of interest

None declared.


We acknowledge the contribution of Koletsa Τ, Giouleme O, Perifanis V, Merakis I.


1. Harris NL, Isaacson PG, Grogan TM, Jaffe ES. Alpha heavy chain disease. Swerdlow SH, Campo E, Harris NL, et al (eds). WHO classification of tumours of hematopoietic and lymphoid tissues. 4th edition, Lyon, 2008, 198-199.
2. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005; 105: 2274-2280.
3. Salem PA, Estephan FF. Immunoproliferative small intestinal disease: current concepts. Cancer J. 2005; 11: 374-382.